Sale!

Del17p(p53) MM CLL FISH Test

Original price was: $176.Current price is: $132.

-25%

The Del17p(p53) MM CLL FISH Test is a specialized genetic analysis that detects deletions in chromosome 17p, specifically targeting the p53 tumor suppressor gene. This advanced diagnostic tool is crucial for patients with Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) as it identifies high-risk genetic abnormalities that significantly impact treatment decisions and prognosis. The test uses Fluorescence In Situ Hybridization (FISH) technology to provide highly accurate results within 3-4 days. Available for only $132 USD, this test helps oncologists determine the most effective treatment strategies and predict disease progression. Early detection of these genetic markers can lead to more personalized therapy approaches and improved patient outcomes.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Del17p(p53) MM CLL FISH Test: Comprehensive Genetic Analysis for Blood Cancers

Understanding the Del17p(p53) MM CLL Test

The Del17p(p53) MM CLL FISH Test represents a breakthrough in molecular diagnostics for hematological malignancies. This specialized genetic test specifically targets chromosome 17p deletions involving the p53 tumor suppressor gene, which plays a critical role in preventing cancer development. When this gene is deleted or mutated, it significantly impacts treatment response and disease prognosis in patients with Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL).

Why This Test Matters

The detection of Del17p(p53) abnormalities is clinically significant because these genetic alterations are associated with aggressive disease behavior, resistance to conventional therapies, and poorer overall survival rates. Identifying these markers early allows healthcare providers to implement more targeted treatment strategies and provide patients with accurate prognostic information.

What the Test Measures and Detects

The Del17p(p53) MM CLL FISH Test utilizes advanced Fluorescence In Situ Hybridization (FISH) technology to precisely identify:

  • Deletions in chromosome 17p region
  • Abnormalities in the p53 tumor suppressor gene
  • Genetic markers associated with high-risk Multiple Myeloma
  • Prognostic indicators for Chronic Lymphocytic Leukemia
  • Treatment resistance patterns

Technical Specifications

  • Methodology: Fluorescence In Situ Hybridization (FISH)
  • Sample Type: Bone Marrow or Peripheral Blood
  • Collection Tube: Sodium Heparin Vacutainer (2ml)
  • Turnaround Time: 3-4 Days
  • Prescription Required: Yes (Doctor’s prescription needed)

Who Should Consider This Test

This genetic analysis is particularly important for:

  • Patients newly diagnosed with Multiple Myeloma
  • Individuals with confirmed Chronic Lymphocytic Leukemia
  • Patients showing resistance to standard chemotherapy
  • Those experiencing rapid disease progression
  • Individuals requiring treatment stratification
  • Patients being evaluated for stem cell transplantation

Clinical Indications

Healthcare providers typically recommend this test when patients present with symptoms such as unexplained bone pain, frequent infections, fatigue, unexplained weight loss, or abnormal blood counts that suggest hematological malignancies. The test is also crucial for monitoring disease progression and treatment response in established cases.

Benefits of Taking the Del17p(p53) MM CLL Test

  • Personalized Treatment Planning: Results guide oncologists in selecting the most effective therapies based on genetic profile
  • Accurate Prognostic Information: Provides valuable insights into disease aggressiveness and expected outcomes
  • Early Intervention Opportunities: Enables timely implementation of targeted therapies
  • Improved Survival Rates: Helps identify patients who may benefit from novel treatment approaches
  • Comprehensive Disease Management: Supports ongoing monitoring and treatment adjustments
  • Informed Decision Making: Empowers patients and physicians with critical genetic information

Understanding Your Test Results

Your Del17p(p53) MM CLL FISH Test results will be carefully interpreted by our expert genetic counselors and hematologists. A positive result indicating deletion of chromosome 17p suggests high-risk disease characteristics that may require more aggressive treatment strategies. Negative results typically indicate standard-risk disease, allowing for conventional treatment approaches. It’s essential to discuss your results with your healthcare provider to understand the specific implications for your treatment plan and long-term management.

Result Interpretation Guidelines

  • Positive Result: Indicates presence of Del17p(p53) abnormality, associated with higher risk disease
  • Negative Result: Suggests absence of this specific genetic alteration
  • Consultation Recommended: All results should be reviewed with your oncologist for proper context

Test Pricing and Availability

Price Type Amount (USD)
Discount Price $132
Regular Price $176

Nationwide Accessibility

We have branches across all major cities in the USA, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing services nationwide.

Book Your Test Today

Take control of your health journey with comprehensive genetic testing. Our Del17p(p53) MM CLL FISH Test provides critical information that can significantly impact your treatment outcomes. Schedule your appointment today by calling our dedicated healthcare line at +1(267) 388-9828 or visit one of our conveniently located branches.

Important Note: This test requires a doctor’s prescription. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning to travel abroad.